Stocklytics Platform
Asset logo for symbol RNA
Avidity Biosciences
RNA67
$44.61arrow_drop_down2.93%-$1.35
High Growth
Asset logo for symbol RNA
RNA67

$44.61

arrow_drop_down2.93%

Performance History

Chart placeholder
Key Stats
Open$45.27
Prev. Close$45.96
EPS-2.96
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range44.65
46.02
52 Week Range4.82
47.05
Ratios
EPS-2.96

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$860.57
Perf. (24h)
arrow_drop_down2.01%-$17.71
Market Cap$790.81B
Price$559.69
Perf. (24h)
arrow_drop_up0.89%$4.98
Market Cap$514.06B
Price$156.32
Perf. (24h)
arrow_drop_up2.61%$3.97
Market Cap$371.20B
Price$125.92
Perf. (24h)
arrow_drop_up1.23%$1.54
Market Cap$318.34B

About Avidity Biosciences (RNA)

Avidity Biosciences Inc (RNA) is a biotechnology company that specializes in the discovery, development, and commercialization of RNA-based therapeutics. With a focus on precision medicine, the company aims to revolutionize the treatment of serious diseases by harnessing the power of RNA. RNA-based therapeutics have the unique ability to target specific disease-causing genes and modulate their expression, offering a potentially safer and more effective alternative to traditional small molecule drugs. Avidity Biosciences is at the forefront of this emerging field, leveraging its proprietary AOC platform to design and develop novel RNA drugs.
The AOC platform combines the advantages of antibody-based therapeutics with nucleic acid technology, enabling the creation of highly specific and potent RNA drugs. By conjugating RNA payloads to antibody-like molecules, Avidity Biosciences is able to deliver the RNA directly to target cells, increasing the drug's efficacy and reducing off-target effects. This targeted approach holds great promise for the treatment of a wide range of diseases, including rare genetic disorders, neurodegenerative diseases, and certain types of cancer.
Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Sarah Boyce
Headquarters
San Diego
Employees
186
Exchange
NASDAQ
add Avidity Biosciences  to watchlist

Keep an eye on Avidity Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Avidity Biosciences 's (RNA) price per share?
The current price per share for Avidity Biosciences (RNA) is $44.61. The stock has seen a price change of -$1.35 recently, indicating a -2.94% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Avidity Biosciences (RNA)?
For Avidity Biosciences (RNA), the 52-week high is $47.05, which is 5.47% from the current price. The 52-week low is $4.82, the current price is 824.56% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Avidity Biosciences (RNA) a growth stock?
Avidity Biosciences (RNA) has shown an average price growth of 0.41% over the past three years. It has received a score of 64 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Avidity Biosciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Avidity Biosciences (RNA) stock price performance year to date (YTD)?
As of the latest data, Avidity Biosciences (RNA) has a year-to-date price change of 387.01%. Over the past month, the stock has experienced a price change of 12.48%. Over the last three months, the change has been 77.45%. Over the past six months, the figure is 341.25%.
help
Is Avidity Biosciences (RNA) a profitable company?
Avidity Biosciences (RNA) has a net income of -$212.22M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 78.02% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2.18K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $9.56M, with a revenue growth rate of 3.64%, providing insight into the company's sales performance and growth. The gross profit is $7.46M. Operating income is noted at -$235.6M. Furthermore, the EBITDA is -$252.84M.
help
What is the market capitalization of Avidity Biosciences (RNA)?
Avidity Biosciences (RNA) has a market capitalization of $4.95B. The average daily trading volume is 1.38M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level